Calliditas Therapeutics AB (STO:CALTX), a speciality pharmaceutical company, announced on Tuesday the grant by the US Food and Drug Administration (FDA) of orphan drug designation (ODD) to the company for the treatment of primary biliary cholangitis (PBC).
PBC, previously known as primary biliary cirrhosis, is an autoimmune disease of the liver, where common symptoms are tiredness, itching and, in more advanced cases, jaundice. PBC is a rare disease, affecting approximately 4.3 people in 10,000 in US.
Also, the company plans to discuss the regulatory pathway for this indication in consultation with the FDA and investigate the most appropriate way forward for this patient population.
Earlier in February 2019, the company was granted ODD by the FDA for AIH. The company plans to agree the regulatory pathway for this indication in consultation with the FDA later this year.
In addition, the company is currently running a global, pivotal phase 3 with study for the treatment of the rare disease IgA nephropathy (IgAN), which has already obtained ODD by the FDA and the European Medicines Agency (EMA). Top line data for IgAN is expected in H2 2020.
Calliditas Therapeutics is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialisation efforts.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial